In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Seres Therapeutics, Inc.

https://www.serestherapeutics.com/

Latest From Seres Therapeutics, Inc.

Getting To Global Is A Hurdle For Cell And Gene Therapies

Only three of the 10 new therapies approved by the US FDA also have been approved in the European Union, while both of the EU gene therapy approvals followed FDA clearance, a Pink Sheet analysis shows.

Regional Comparisons Gene Therapy

Deal Watch: Vanda Gets Competing Offer From Cycle After Unsolicited Future Pak Bid

Plus deals involving GSK/Elsie, Lilly/QurAlis, Gilead/Cartography as well as tech transfer announcements and deals in brief.

Deal Watch Business Strategies

Bloom Harnesses Gut-Brain Axis To Develop ‘Bugs As Drugs’ For Rare Neurological Disease

Emerging Company Profile Companies

Seres And Ferring Go Head-To-Head In Recurrent C. Difficile Market

After the historic approvals of Seres’ and Ferring’s microbiome-based treatments for recurrent Clostridioides difficile infection, the two companies are waiting to see who dominates the $1bn market. Physicians say patients will steer the choice of treatments.

Strategy Commercial
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
  • Other Names / Subsidiaries
    • Seres Health, Inc.
UsernamePublicRestriction

Register